Sequencing the 19 tumors initially found to be NRAS- and BRAF-wild-type (15%) (applying the primary smaller 16 gene panel), with a larger panel covering 29 genes recurrently mutated in cutaneous or uveal melanoma [39], we only identified one MAP2K1 mutation (305_307delAGA, E102_I103V, c.309_311delCAA K104del), highly reminiscent of E102_I103del mutations reported to be activating with similar consequences to BRAF mutations [40]. This evidence concerns the gene MAP2K1 and uveal melanoma.